3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
Primary Myelofibrosis
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
6
Injections
6
senaparib
4
toripalimab
3
tislelizumab
3
Bevacizumab
3
sintilimab
2
Technetium
2
Specimen Handling
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Carboplatin
2
Blood Specimen Collection
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
tazemetostat
1
spartalizumab
1
sacituzumab govitecan
1
rucaparib
1
osimertinib
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
cemiplimab
1
cedazuridine
1
atezolizumab
1
WW Domain-Containing Oxidoreductase
1
Ultrasonography, Doppler
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
Blood Component Removal
×
1 year
×
Clear all
NCT07137312
2025-12-23
Ex Vivo Expansion (ACT-X)
Mayo Clinic
Recruiting
24 enrolled